Thienopyrimidines for pharmaceutical compositions

A compound of the general formula (1)

• wherein X is O, S, SO2, CH2, CHR1a, CR1aR1b, CH(halogen), C(halogen)2, C═O, C(O)NR1a, NH or NR1a, wherein R1a and R1b are C1-6 alkyl, C1-6 alkyl C3-10 cycloalkyl, C3-10 cycloalkyl, C1-6 alkyl 3 to 10 membered heterocycloalkyl comprising at least one heteroatom selected from N, S and O, 3 to 10 membered heterocycloalkyl comprising at least one heteroatom selected from N, S and O, wherein R1a and R1b are optionally substituted with one or more R9;
• R1 is hydrogen, C1-6 alkyl, C1-6 alkyl C3-10 cycloalkyl, C3-10 cycloalkyl, C1-6 alkyl 3 to 10 membered heterocycloalkyl comprising at least one heteroatom selected from N, S and O, 3 to 10 membered heterocycloalkyl comprising at least one heteroatom selected from N, S and O, C6-10 aryl, C1-6 alkyl C6-10 aryl, C5-10 heteroaryl comprising at least one heteroatom selected from N, S and O, C1-6 alkyl C5-10 heteroaryl comprising at least one heteroatom selected from N, S and O, wherein R1 is optionally substituted with one or more R9;
• or if X is NR1a, CHR1a, C(O)NR1a or CR1aR1b, R1 may form a carbocyclic or heterocyclic ring with R1a and the N or C atom to which they are attached, which may contain one or more additional heteroatoms selected from N, S and O, which may be substituted with one or more R9;
• R2 and R3 are the same or different and are independently selected from hydrogen, C1-6 alkyl, C1-6 alkyl C3-10 cycloalkyl, C3-10 cycloalkyl, C6-10 aryl, C1-6 alkyl C6-10 aryl, C5-10 heteroaryl comprising at least one heteroatom selected from N, S and O, C1-6 alkyl C5-10 heteroaryl comprising at least one heteroatom selected from N, S and O, C1-6 alkyl 3 to 10 membered heterocycloalkyl comprising at least one heteroatom selected from N, S and O, 3 to 10 membered heterocycloalkyl comprising at least one heteroatom selected from N, S and O, or together with the C atoms that they are attached to form a C3-7 cycloalkyl or a 3 to 10 membered heterocycloalkyl group, wherein R2 and R3 are optionally substituted with one or more R9, R2 may also be R9 and R3 may also be R10;
• R4 is hydrogen, C1-4 alkyl, urea, thiourea or acetyl optionally substituted with one or more R9;
• or R4 may form a 5 or 6 membered heterocyclic ring with R1:
• R5, R6, R7 and R8 are the same or different and are independently selected from H or R9;
• R9 is independently halogen;
• CN;
• COOR11;
• OR11;
• C(O)N(R11R11a);
• S(O)2N(R11R11a);
• S(O)N(R11R11a);
• S(O)2R11;
• N(R11)S(O)2N(R11aR11b);
• SR11;
• N(R11R11a);
• OC(O)R11;
• N(R11)C(O)R11a;
• N(R11)S(O)2R11a;
• N(R11)S(O)R11a;
• N(R11)C(O)N(R11aR11b);
• N(R11)C(O)OR11a;
• OC(O)N(R11R11a);
• oxo (═O), where the ring is at least partially saturated;
• C(O)R11;
• C1-6 alkyl;
• phenyl;
• C3-7 cycloalkyl;
• or heterocyclyl, wherein C1-6 alkyl;
• phenyl;
• C3-7 cycloalkyl;
• and heterocyclyl are optionally substituted with one or more R10;
• R10 is independently halogen;
• CN;
• OR11;
• S(O)2N(R11R11a);
• S(O)N(R11R11a);
• S(O)2R11;
• N(R11)S(O)2N(R11aR11b);
• SR11;
• N(R11R11a);
• OC(O)R11;
• N(R11)C(O)R11a;
• N(R11)S(O)2R11a;
• N(R11)S(O)R11a;
• N(R11)C(O)N(R11aR11b);
• N(R11)C(O)OR11a;
• OC(O)N(R11R11a);
• oxo (═O), where the ring is at least partially saturated;
• C(O)R11;
• C1-6 alkyl;
• phenyl;
• C3-7 cycloalkyl;
• or heterocyclyl, wherein C1-6 alkyl;
• phenyl;
• C3-7 cycloalkyl;
• and heterocyclyl are optionally substituted with one or more R9;
• R11, R11a, R11b are independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkyl C3-10 cycloalkyl, C3-10 cycloalkyl, C1-6 alkyl 3 to 10 membered heterocycloalkyl comprising at least one heteroatom selected from N, S and O, 3 to 10 membered heterocycloalkyl comprising at least one heteroatom selected from N, S and O, C6-10 aryl, 5 to 10 membered heteroaryl comprising at least one heteroatom selected from N, S and O, wherein R11, R11a, R11b are optionally substituted with one or more R9;
• or a metabolite, prodrug or a pharmaceutically acceptable salt thereof.